LANCL2 Ligands Modulate Immunometabolic Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as infectious diseases, hyperproliferative disorders, inborn errors of metabolism, chronic immunometabolic diseases, autoimmune diseases, organ transplant rejection, inflammatory disorders, and chronic pain often have limitations in efficacy and safety, particularly in addressing the underlying immunometabolic imbalances.
Innovation Solution
The use of a class of compounds, specifically those of the formula Z-Y-Q-Y′-Z′, or their pharmaceutically acceptable salts or esters, which target and activate LANCL2, eliciting beneficial immunometabolic responses in cells to treat various disease conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for diseases such as infectious diseases, autoimmune diseases, and inflammatory disorders, then disease symptoms can be managed, but efficacy is limited and safety concerns arise due to inability to address underlying immunometabolic imbalances
Solution Approach 1:
The patent introduces LANCL2 as a molecular intermediary target that mediates between metabolic and immune pathways. By designing compounds that specifically bind to and activate LANCL2, the invention creates a bridging mechanism that simultaneously addresses immunometabolic imbalances, thereby improving therapeutic efficacy while reducing safety concerns associated with conventional treatments that fail to address this intersection.
Solution Approach 2:
The invention changes the therapeutic parameter from targeting single immune or metabolic pathways separately to targeting the immunometabolic interface through LANCL2 activation. This parameter change enables simultaneous modulation of both immune and metabolic functions, resolving the contradiction by addressing the root cause (immunometabolic imbalance) rather than just symptoms, thereby improving efficacy while enhancing safety.
2Ease of operation
If conventional therapies are administered to treat inflammatory disorders and metabolic diseases, then some symptom relief is achieved, but the treatments fail to address the root cause of immunometabolic imbalances
Solution Approach 1:
The patent employs preliminary action by targeting LANCL2 activation before inflammatory symptoms fully develop or worsen. By intervening at the immunometabolic level through LANCL2 modulation, the treatment prevents the progression to severe inflammatory states rather than merely managing established symptoms, thereby addressing the root cause while maintaining ease of operation through a single targeted mechanism.
3Device complexity
If single-target therapies are used for immune or metabolic conditions, then treatment simplicity is maintained, but comprehensive efficacy is reduced due to inability to modulate both immune and metabolic functions simultaneously
Solution Approach 1:
The patent applies universality by designing LANCL2-activating compounds that perform multiple therapeutic functions through a single target mechanism. LANCL2 itself is a universal node that connects both immune and metabolic pathways, so activating it produces multi-functional effects: modulating inflammation, improving metabolic parameters, and enhancing overall immunometabolic health. This achieves comprehensive efficacy while maintaining treatment simplicity, as one compound targets one receptor that controls multiple downstream processes.
Data Source
AI summary
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds. The compounds and cells can be used to treat a number of conditions, including infectious diseases, hyperproliferative disorders, inborn errors of metabolism, chronic immunometabolic diseases, autoimmune diseases, organ transplant rejection, inflammatory disorders, and chronic pain, among others.